Related references
Note: Only part of the references are listed.Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital
J. Torres-Jimenez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case
Zoe Apalla et al.
DERMATOLOGIC THERAPY (2021)
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert et al.
EUROPEAN JOURNAL OF CANCER (2021)
Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database
F. Cohen Aubart et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study
Sandra Huynh et al.
MELANOMA RESEARCH (2020)
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
Eleftheria Chorti et al.
EUROPEAN JOURNAL OF CANCER (2020)
Dermal fillers may induce late-onset adverse skin reactions in patients under BRAF inhibitors
A. Ortiz-Brugues et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma
Manuel Rubio-Rivas et al.
AUTOIMMUNITY REVIEWS (2020)
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
Andrea Boutros et al.
FRONTIERS IN IMMUNOLOGY (2020)
Panniculitis in association with target therapy in melanoma patient, what the dermatologist should know: A case report
Victor Manubens-Vargas et al.
MEDWAVE (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
Hilal Eser Orturk et al.
TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY (2020)
Immune checkpoint inhibitors and the development of granulomatous reactions
Christine M. Cornejo et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients
A. Amoura et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events
Heike C. Hawerkamp et al.
ALLERGY (2019)
TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma
Gena M. Damento et al.
MAYO CLINIC PROCEEDINGS (2019)
BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases
Eugene Liat Hui Ong et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2019)
Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
Gabrielle Giet et al.
CASE REPORTS IN DERMATOLOGY (2019)
Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors
Florence Assan et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2019)
Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib
J. K. Winkler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Drug-Induced Sarcoidosis-Like Reactions
Amit Chopra et al.
CHEST (2018)
Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis)
Shelby L. Kubicki et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Sarcoidosis: a state of the art review from the Thoracic Society of Australia and New Zealand
Hasib Ahmadzai et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Sarcoid-like reactions in patients receiving modern melanoma treatment
Florentia Dimitriou et al.
MELANOMA RESEARCH (2018)
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma
Panagiotis T. Diamantopoulos et al.
MELANOMA RESEARCH (2018)
Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis
Lily Chen et al.
PEDIATRIC DERMATOLOGY (2018)
Epidemiology of sarcoidosis: current findings and future directions
Elizabeth V. Arkema et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Vemurafenib-Induced Granulomatous Hepatitis
Erin K. Spengler et al.
HEPATOLOGY (2017)
Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma A case report
Mehdi Maanaoui et al.
MEDICINE (2017)
BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response
Celine Desvignes et al.
MELANOMA RESEARCH (2017)
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
Fleur Cohen Aubart et al.
BLOOD (2017)
Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor
Lorena Leal et al.
JOURNAL OF DERMATOLOGY (2016)
Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma
Nisha S. Ramani et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2015)
BRAF Inhibitor–Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma
Maria C. Garrido et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2015)
Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations
R. Sinha et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation
Coralie Lheure et al.
DERMATOLOGY (2015)
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
Henrike Tolk et al.
MELANOMA RESEARCH (2015)
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib
Yanina J. Jansen et al.
MELANOMA RESEARCH (2015)
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Michael Krauthammer et al.
NATURE GENETICS (2015)
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors forMetastatic Melanoma
Giuliana Carlos et al.
JAMA DERMATOLOGY (2015)
BRAF-inhibition and tumor immune suppression
Shannon M. Steinberg et al.
ONCOIMMUNOLOGY (2015)
Dabrafenib-associated necrobiotic granulomatous reaction
Giuliana Carlos et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2014)
Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment
James S. Wilmott et al.
JOURNAL OF IMMUNOLOGY (2014)
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Alexander M. Menzies et al.
LANCET ONCOLOGY (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BRAF inhibitors in cancer therapy
Carolina Hertzman Johansson et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Cutaneous Granulomatous Eruption and Successful Response to Potent Topical Steroids in Patients Undergoing Targeted BRAF Inhibitor Treatment for Metastatic Melanoma
June J. Park et al.
JAMA DERMATOLOGY (2014)
Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?
Georgi Tchernev et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2014)
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
L. Boussemart et al.
ANNALS OF ONCOLOGY (2013)
Sarcoidosis associated with vemurafenib
A. Adam et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases
J. S. Green et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management
Lisa Zimmer et al.
ARCHIVES OF DERMATOLOGY (2012)
Phase III, randomized, open-label, multicenter trial (BREAK3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sarcoidosis: A comprehensive review and update for the dermatologist Part II. Extracutaneous disease
Adele Haimovic et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sarcoidosis is a Th1/Th17 multisystem disorder
Monica Facco et al.
THORAX (2011)
Immune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosis
Vyacheslav Palchevskiy et al.
FIBROGENESIS & TISSUE REPAIR (2011)
Sarcoidosis and Melanoma: A Referral Center Study of 1,199 Cases
Pascal Seve et al.
DERMATOLOGY (2009)
Interstitial granulomatous lesions as part of the spectrum of presenting cutaneous signs in pediatric sarcoidosis
Eun J. Kwon et al.
PEDIATRIC DERMATOLOGY (2007)
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies
Gerald Saldanha et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
